

Regimen Reference Order

THOR – FOLFOX (esophageal) with concurrent radiation

ARIA: ESOPH – [FOLFOX + RT]

Planned Course: Every 14 days for 6 cycles (Cycles 1, 2 and 3 with concurrent radiation)

Indication for Use: Esophageal Cancer

CVAD: Required (Ambulatory Pump)

Proceed with treatment if:

ANC equal to or greater than $1.5 \times 10^9/L$ AND Platelets equal to or greater than $75 \times 10^9/L$

❖ **Contact Physician if parameters are not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – THOR – FOLFOX (esophageal) with concurrent radiation

Establish primary solution 500 mL of: D5W

Drug	Dose	CCMB Administration Guideline
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy
oxaliplatin	85 mg/m ²	IV in D5W 500 mL over 2 hours oxaliplatin and leucovorin may be infused over the same 2 hour period using a Y-site connector <i>Concentration dependent drug: Pharmacy will adjust diluent volume to ensure drug stability</i>
leucovorin	200 mg/m ²	IV in D5W 250 mL over 2 hours
fluorouracil	400 mg/m ²	IV push over 5 minutes
fluorouracil	1600 mg/m ²	IV in D5W continuously over 46 hours by ambulatory infusion device

All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See THOR DSG – Dose Banding document for more information

In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’

REQUIRED MONITORING

All Cycles

- CBC, serum creatinine, urea, electrolytes, liver enzymes and total bilirubin as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
dexamethasone	8 mg	Orally once daily on Days 2 and 3
prochlorperazine	10 mg	Orally every 6 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- Ensure patient has received a home chemotherapy spill kit and instructions for use
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Numerous dosing variations exist for FOLFOX and depend on the primary cancer diagnosis
- oxaliplatin causes cold intolerance and laryngopharyngeal dysesthesia
 - no ice chips or cold drinks
- oxaliplatin may cause progressive, irreversible neuropathy
 - dose modification may be required
- Cycle 1 is usually started on the first day of radiation therapy
- Cycles 4, 5 and 6 will be given after radiation is complete
- Since FOLFOX is given concurrently with radiation, site restrictions are in place for Cycles 1, 2 and 3